Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$7.53 USD
-0.25 (-3.21%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $7.51 -0.02 (-0.27%) 7:08 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zevra Therapeutics (ZVRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.75 | $24.00 | $18.00 | 153.86% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Zevra Therapeutics comes to $19.75. The forecasts range from a low of $18.00 to a high of $24.00. The average price target represents an increase of 153.86% from the last closing price of $7.78.
Analyst Price Targets (4 )
Broker Rating
Zevra Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/6/2024 | Roth Capital Partners | Jonathan Aschoff | Strong Buy | Strong Buy |
8/30/2024 | William Blair | Sami Corwin | Not Available | Strong Buy |
8/5/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
7/9/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
5/9/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
4/2/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $19.75 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 72 of 253 |
Current Quarter EPS Est: | -0.43 |
ZVRA FAQs
Zevra Therapeutics, Inc. (ZVRA) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Zevra Therapeutics, Inc. (ZVRA) is $19.75. The current on short-term price targets is based on 4 reports.
The forecasts for Zevra Therapeutics, Inc. (ZVRA) range from a low of $18 to a high of $24. The average price target represents a increase of $153.86 from the last closing price of $7.78.
The current UPSIDE for Zevra Therapeutics, Inc. (ZVRA) is 153.86%
Based on short-term price targets offered by four analysts, the average price target for Zevra Therapeutics comes to $19.75. The forecasts range from a low of $18.00 to a high of $24.00. The average price target represents an increase of 153.86% from the last closing price of $7.78.